Drug Shortage Report for MORPHINE SULFATE INJECTION, USP

Last updated on 2025-04-26 History
Report ID 253988
Drug Identification Number 02482746
Brand name MORPHINE SULFATE INJECTION, USP
Common or Proper name MORPHINE SULFATE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) MORPHINE SULFATE
Strength(s) 10MG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging sizes (GTIN)

Click here to see a list of all reports for this drug.

(See additional packaging sizes)
Additional packaging sizes 1mL
ATC code N02AA
ATC description OPIOIDS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2025-04-25
Estimated end date 2025-06-18
Actual end date
Shortage status Actual shortage
Updated date 2025-04-26
Company comments Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Morphine Sulfate Injection, USP 10 mg / mL SD Vial 1 mL effective April 25, 2025, until June 18, 2025.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v3 2025-04-26 English Compare
v2 2025-04-03 French Compare
v1 2025-04-03 English Compare

Showing 1 to 3 of 3